Teladoc Health Inc. (NYSE:TDOC) shares are up on Tuesday.
TDOC Reported Stronger-Than-Expected Quarterly Results
In February, Teladoc Health reported a quarterly loss of 14 cents per share, which was better than the consensus loss of 18 cents.
Additionally, sales increased to $642.27 million, surpassing the expected $635.24 million, driven by a 24% rise in other revenue streams, although access fees revenue fell by 4%.
Teladoc Health expects the first quarter 2026 loss to be between 35-45 cents compared to the consensus loss of 25 cents, with sales of $598-$620 million versus the consensus of $633.75 million.
The telehealth company sees a fiscal 2026 loss of 70 cents to $1.10, with sales of $2.47 billion to $2.59 billion, compared to the consensus of 76 cents and $2.55 billion, respectively.
Analyst Reaction
Deutsche Bank on Monday upgraded the virtual health care provider, citing a compelling valuation and a potential exit scenario. Deutsche upgraded TDOC from Hold to Buy, with a price forecast of $11
After the fourth quarter earnings, BTIG updated its earnings model for Teladoc Health.
David Larsen on Monday wrote, “While results in the quarter were decent, we remain generally cautious on TDOC.”
Larsen wrote that “Given a difficult macro environment, a seemingly saturated tele-health market, and a highly competitive behavioral health market, we remain cautious on TDOC.” BTIG maintains the Neutral rating on Teladoc Health.
Oppenheimer reiterated Teladoc Health with an Outperform and lowered the price target from $12 to $7.
Citigroup maintained Teladoc Health with a Neutral and lowered the price target from $9 to $6.
Piper Sandler reiterated Teladoc Health with an Overweight rating and lowered the price target from $12 to $9.
BMO Capital maintained Teladoc with a Market Perform and lowered the price target from $8 to $5.
TD Cowen maintained the stock with a Hold and lowered the price target from $8 to $6.
Leerink Partners maintained Teladoc Health with a Market Perform and lowered the price target from $8.5 to $5.5.
Canaccord Genuity kept the Buy rating and lowered the price target from $12 to $10.
TDOC Shows Short-Term Strength Amid Long-Term Struggles
The stock is currently trading 21.8% above its 20-day simple moving average (SMA) but is 12.5% below its 100-day SMA, indicating some short-term strength while struggling in the longer term.
Over the past 12 months, shares have decreased 40.65% and are currently positioned closer to their 52-week lows than highs.
The RSI is at 52.22, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at -0.1341, above its signal line at -0.2551, indicating bullish momentum.
The combination of neutral RSI and bullish MACD suggests mixed momentum. Traders should watch for potential breakouts or reversals as the stock navigates its current technical landscape.
- Key Resistance: $6.50
- Key Support: $5.00
TDOC Price Action: Teladoc Health shares were up 5.57% at $5.59 at the time of publication on Tuesday, according to Benzinga Pro data.
Image Via Teladoc
This article Teladoc Health Stock Pops - Here's Why originally appeared on Benzinga.com
.
